×

COVID-19: -

Our Commitment to Client Service & Investor Communications
Life Sciences

genedrive Plc

Based on Epistem's proprietary technology, the Genedrive® molecular diagnostic system has been developed as an affordable next generation genotyping and sequence analysis device, providing rapid detection and diagnosis in approximately 45-75 minutes depending on the test. Genedrive® has been designed as a simple-to-use handheld device with high multiplexing capability.
The first test developed on the Genedrive® is the HCV-ID test, which allows small/medium laboratories to test for hepatitis infection, thus speeding up diagnosis and treatment, and improving patients’ prognosis. Genedrive® analyses nucleic acids from fresh or stored samples or biospecimens.

Market: AIM

Ticker: GDR

www.genedriveplc.com

Lead analyst: Dr Dorothea Hill

Request a meeting

If you'd like to be introduced to the team at genedrive Plc, get in touch.

Request a meeting